中枢神经系统疾病的 RNA 干扰治疗的最新进展。
Recent advances in RNA interference therapeutics for CNS diseases.
机构信息
Interdisciplinary program in Genetics, University of Iowa, Iowa City, IA 52242, USA.
出版信息
Neurotherapeutics. 2013 Jul;10(3):473-85. doi: 10.1007/s13311-013-0183-8.
Abstract
Over the last decade, RNA interference technology has shown therapeutic promise in rodent models of dominantly inherited brain diseases, including those caused by polyglutamine repeat expansions in the coding region of the affected gene. For some of these diseases, proof-of concept studies in model organisms have transitioned to safety testing in larger animal models, such as the nonhuman primate. Here, we review recent progress on RNA interference-based therapies in various model systems. We also highlight outstanding questions or concerns that have emerged as a result of an improved (and ever advancing) understanding of the technologies employed.
摘要
在过去的十年中，RNA 干扰技术在显性遗传性脑疾病的啮齿动物模型中显示出了治疗潜力，包括那些由受影响基因编码区的多聚谷氨酰胺重复扩展引起的疾病。对于其中一些疾病，在模式生物中进行的概念验证研究已经过渡到更大动物模型（如非人类灵长类动物）的安全性测试。在这里，我们回顾了各种模型系统中基于 RNA 干扰的治疗方法的最新进展。我们还强调了由于对所使用技术的理解（以及不断提高）而出现的一些悬而未决的问题或关注点。
相似文献
1
Recent advances in RNA interference therapeutics for CNS diseases.
Neurotherapeutics. 2013 Jul;10(3):473-85. doi: 10.1007/s13311-013-0183-8.
2
Development of microRNA-based therapeutics for central nervous system diseases.
Eur J Pharmacol. 2023 Oct 5;956:175956. doi: 10.1016/j.ejphar.2023.175956. Epub 2023 Aug 2.
3
RNAi therapeutics for CNS disorders.
Brain Res. 2010 Jun 18;1338:112-21. doi: 10.1016/j.brainres.2010.03.038. Epub 2010 Mar 20.
4
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.
Hum Mol Genet. 2016 Apr 15;25(R1):R53-64. doi: 10.1093/hmg/ddv442. Epub 2015 Oct 26.
5
Use of gene therapy in central nervous system repair.
Acta Neurol Scand. 2004 Jan;109(1):1-8. doi: 10.1046/j.1600-0404.2003.00240.x.
6
The emerging therapeutic role of RNA interference in disorders of the central nervous system.
Clin Pharmacol Ther. 2011 Mar;89(3):450-4. doi: 10.1038/clpt.2010.312. Epub 2011 Jan 19.
7
RNA-based therapeutics for neurological diseases.
RNA Biol. 2022;19(1):176-190. doi: 10.1080/15476286.2021.2021650. Epub 2021 Dec 31.
8
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.
9
Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mol Pharm. 2021 Apr 5;18(4):1491-1506. doi: 10.1021/acs.molpharmaceut.0c01238. Epub 2021 Mar 18.
10
Delivery of siRNA into the blood-brain barrier: recent advances and future perspective.
Ther Deliv. 2012 Apr;3(4):417-20. doi: 10.4155/tde.12.22.
引用本文的文献
1
CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting.
Pharm Res. 2023 Jan;40(1):77-105. doi: 10.1007/s11095-022-03433-5. Epub 2022 Nov 15.
2
Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.
Neural Regen Res. 2022 Aug;17(8):1717-1725. doi: 10.4103/1673-5374.332129.
3
Non-viral Vector Mediated RNA Interference Technology for Central Nerve System Injury.
DNA RNA Nanotechnol. 2016;3(1):14-22. doi: 10.1515/rnan-2016-0003. Epub 2016 Aug 25.
4
IGFBP‑rP1‑silencing promotes hypoxia‑induced angiogenic potential of choroidal endothelial cells via the RAF/MEK/ERK signaling pathway.
Mol Med Rep. 2020 Dec;22(6):4837-4847. doi: 10.3892/mmr.2020.11578. Epub 2020 Oct 11.
5
Oligonucleotide therapeutics in neurodegenerative diseases.
RNA Biol. 2018;15(6):707-714. doi: 10.1080/15476286.2018.1454812. Epub 2018 Jun 1.
6
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.
Hum Mol Genet. 2016 Apr 15;25(R1):R53-64. doi: 10.1093/hmg/ddv442. Epub 2015 Oct 26.
7
A brief perspective on neural cell therapy.
Mol Cell Ther. 2014 Jan 8;2:2. doi: 10.1186/2052-8426-2-2. eCollection 2014.
8
Inducible and combinatorial gene manipulation in mouse brain.
Front Cell Neurosci. 2015 Apr 21;9:142. doi: 10.3389/fncel.2015.00142. eCollection 2015.
9
The role of the immune system in triplet repeat expansion diseases.
Mediators Inflamm. 2015;2015:873860. doi: 10.1155/2015/873860. Epub 2015 Mar 22.
10
Mechanisms of RNA-induced toxicity in CAG repeat disorders.
Cell Death Dis. 2013 Aug 1;4(8):e752. doi: 10.1038/cddis.2013.276.
本文引用的文献
1
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles.
Mol Ther. 2008 Jul;16(7):1252-1260. doi: 10.1038/mt.2008.100. Epub 2016 Dec 8.
2
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.
Gene Ther. 2013 Apr;20(4):450-9. doi: 10.1038/gt.2012.101. Epub 2013 Jan 10.
3
Designing functional siRNA with reduced off-target effects.
Methods Mol Biol. 2013;942:57-68. doi: 10.1007/978-1-62703-119-6_3.
4
Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice.
J Neurosci. 2012 Sep 12;32(37):12786-96. doi: 10.1523/JNEUROSCI.1643-12.2012.
5
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.
Mol Ther. 2013 Jan;21(1):109-18. doi: 10.1038/mt.2012.186. Epub 2012 Sep 11.
6
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse.
Nucleic Acids Res. 2013 Jan 7;41(1):e9. doi: 10.1093/nar/gks797. Epub 2012 Aug 31.
7
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
Cell. 2012 Aug 31;150(5):895-908. doi: 10.1016/j.cell.2012.08.002.
8
Single-stranded siRNAs activate RNAi in animals.
Cell. 2012 Aug 31;150(5):883-94. doi: 10.1016/j.cell.2012.08.014.
9
Singles engage the RNA interference pathway.
Cell. 2012 Aug 31;150(5):873-5. doi: 10.1016/j.cell.2012.08.008.
10
Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224.
Nucleic Acids Res. 2012 Oct;40(19):9863-75. doi: 10.1093/nar/gks712. Epub 2012 Jul 30.
Zotero 插件